IP Verse

Compositions Comprising Sphingosine I Phosphate (Sip) Receptor Modulators

Patent No. EP2952177 (titled "Compositions Comprising Sphingosine I Phosphate (Sip) Receptor Modulators") was filed by Novartis on Oct 9, 2008. The application was issued on Jan 20, 2021.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
TEVA PHARMACEUTICALSMay 4, 2023D YOUNG
TEVA PHARMACEUTICALSSep 22, 2022D YOUNG
ACCORD HEALTHCAREOct 20, 2021HOFFMANN EITLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2952177

NOVARTIS
Application Number
EP15173766A
Filing Date
Oct 9, 2008
Status
Granted And Under Opposition
Dec 18, 2020
Publication Date
Jan 20, 2021
External Links
Slate, Register , Google Patents